Advertisement

Research Article Free access | 10.1172/JCI118343

Genetic instability in patients with Hodgkin's disease undergoing chemotherapy.

J M Abdallah, D P Lombardi, and I R Kirsch

National Cancer Institute--Navy Medical Oncology Branch, Bethesda, Maryland 20889-5105, USA.

Find articles by Abdallah, J. in: PubMed | Google Scholar

National Cancer Institute--Navy Medical Oncology Branch, Bethesda, Maryland 20889-5105, USA.

Find articles by Lombardi, D. in: PubMed | Google Scholar

National Cancer Institute--Navy Medical Oncology Branch, Bethesda, Maryland 20889-5105, USA.

Find articles by Kirsch, I. in: PubMed | Google Scholar

Published December 1, 1995 - More info

Published in Volume 96, Issue 6 on December 1, 1995
J Clin Invest. 1995;96(6):2744–2747. https://doi.org/10.1172/JCI118343.
© 1995 The American Society for Clinical Investigation
Published December 1, 1995 - Version history
View PDF
Abstract

We have studied the effect of chemotherapy on the level of a particular kind of genetic instability in patients with Hodgkin's disease. The particular type of genetic instability assayed is exemplified by trans-rearrangements between two (rather than within one) T cell antigen receptor. 16 patients were studied during their course of treatment. Presentation samples were available for 13 of these patients; 9 of them showed an increase in the level of trans-rearrangements during their exposure to chemotherapeutic agents (P < 0.043). All patients for whom posttherapy samples were available (10 out of 16) showed a return to baseline levels of trans-rearrangements 1-5 mo after completion of therapy (P < 0.03). Thus, this assay appears to be a marker for the "destabilizing" effects of certain chemotherapeutic agents.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (December 1, 1995): No description
Advertisement
Advertisement